<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zarifyan, Alla</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Filippatos, Gerasimos</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ARTS-HF Study</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-10-21 10:14:30</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-16</style></pages><abstract><style  face="normal" font="default" size="100%">ARTS-HF study demonstrated that finerenone had a comparable efficacy with eplerenone in reducing N-terminal pro-brain natriuretic peptide and a greater efficacy in reducing the incidence of the composite of all-cause death, cardiovascular hospitalization, or emergency presentation for worsening chronic heart failure in patients with heart failure with reduced ejection fraction and type 2 diabetes or chronic kidney disease. However, caution is required in interpreting the results because it was an exploratory, underpowered study.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>